Loncom Pharma's Osimertinib Mesylate APIs are revolutionary in treating non-small cell lung cancer with specific genetic markers. These APIs selectively inhibit EGFR mutations, offering patients a targeted therapy that can lead to better outcomes and a reduced side effect profile.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
